Looking Into the Future of Life Sciences Industry

The life sciences industry’s impressive response to the COVID-19 was made possible by unprecedented collaboration between the pharmaceutical, medical diagnostics, and medical devices industries. This spurred a massive influx of capital that is still buoying the market, despite recent bumps and headwinds. In a recent Life Science Leader, Darren Jones lays the trends he predicts will define near-future of the life sciences industry.

According to Jones, “In 2021, there were a record number of industry IPOs, including many completed via special purpose acquisition companies (SPACs). In many respects, the equity markets are still adjusting to these new entrants, but this is unlikely to stop the flow of new companies seeking capital. That need for capital is being felt throughout the development stages, from inflation-impacted increases in clinical development as well as manufacturing and supply chain costs, to increased demand and difficulty in satisfying the outcomes evidence expectations of payers.”

To read more, click here.

(Source: Life Science Leader, May 2^nd, 2022)